White Paper

Genome-Editing: The Value of CRISPR’s Intellectual Property

The CRISPR IP landscape can often seem like a labyrinth. ARK aims to summarize the key CRISPR stakeholders and collaborations, including: i) licenses from patent holders, ii) sub-licenses from surrogates to collaborators, iii) areas of CRISPR research, and iv) exclusive vs. non-exclusive licenses.

ARK believes the IP battle will result in cross-licensing agreements and the global proliferation of CRISPR technology. While it may be years until we have a resolution, the benefits of CRISPR are already tangible. To download the full white paper, please fill out the form.

You also may be interested in our white paper:

CRISPR Genome-Editing Market Opportunity and Key Players.
You are leaving
By clicking below you acknowledge that you are navigating away from and will be connected to ARK Investment Management LLC manages both web domains. Please take note of ARK’s privacy policy, terms of use, and disclosures that may vary between sites.